Costin D

References (1)

Title : Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer - Aggarwal_2026_J.Immunother.Cancer_14_

Author(s) : Aggarwal R , Zhang J , Monk P , Zhu X , Jones R , Linch M , Costin D , de Bono J , Karsh LI , Petrylak DP , Zhang L , Deshpande R , Borderies P , Huang J , O'Neill V , Donkor M , Tagawa S

Ref : J Immunother Cancer , 14 : , 2026

Abstract :

PubMedSearch : Aggarwal_2026_J.Immunother.Cancer_14_

PubMedID: 42114950

Costin D

References (1)

1. Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer - Aggarwal_2026_J.Immunother.Cancer_14_